Publications by authors named "A van Laethem"

Introduction: As the COVID-19 pandemic becomes an endemic state, still many questions remain regarding the risks and impact of SARS-CoV-2 infection and vaccination in patients with immune-mediated inflammatory diseases (IMIDs) who were excluded from the phase 3 COVID-19 vaccination trials.

Methods: The BELCOMID study collected patient data and serological samples from a large, multicentric IMID patient cohort that was prospectively followed during sequential stages of the pandemic. Patients were stratified according to vaccination status into five groups across three sampling periods.

View Article and Find Full Text PDF
Article Synopsis
  • Phage therapy is a new treatment approach for multidrug-resistant infections, specifically targeting the challenges posed by hidradenitis suppurativa (HS), a chronic inflammatory condition with painful flare-ups that greatly affect quality of life.
  • Despite advancements in treatments like adalimumab, many patients do not respond to conventional therapies, necessitating innovative solutions such as phage therapy, which targets specific harmful bacteria in HS lesions.
  • Research indicates that using phage therapy may not only help manage HS but could also enhance understanding of bacterial roles and immune responses involved in the disease.
View Article and Find Full Text PDF

Background: Crohn's disease (CD) is an inflammatory bowel disease (IBD) that, besides gastrointestinal symptoms, may encompass extra-intestinal symptoms, such as dermatological manifestations. Of those, metastatic CD (MCD) is a rare extra-intestinal manifestation for which the management is uncertain.

Methods: We conducted a retrospective case series of patients with MCD seen at the University hospital Leuven, Belgium, combined with an overview of the recent literature.

View Article and Find Full Text PDF

Background: The risks and impact of COVID19 disease and vaccination in patients with Immune Mediated Inflammatory Diseases (IMID) remain incompletely understood. IMID patients and particularly patients receiving immunosuppressive treatment were excluded from the original, registrational phase-3 COVID19 vaccination efficacy and safety trials. Real-world observational data can help to fill this gap in knowledge.

View Article and Find Full Text PDF